SQZ Biotechnologies Co

SQZ Biotechnologies Co. is a clinical-stage biotechnology company, which engages in developing cell therapies for patients with cancer, infectious diseases, and other serious conditions. It operates through SQZ cell therapy platform, which uses membrane disruption to deliver material into cells. The company was founded by Robert S. Langer Jr., Klavis F. Jensen, Agustin Lopez Marquez, and Armon Sharei in March 2013 and is headquartered in Watertown, MA.

VANCOUVER, British Columbia--(BUSINESS WIRE)--STEMCELL Technologies is pleased to announce the acquisition of substantially all assets of SQZ Biotechnologies Company (SQZ)—a Massachusetts-based biotech known for its game-changing method of introducing a variety of therapeutic cargo into cells by squeezing them (mechanoporation) rather than using electricity (electroporation). This transaction, which was approved by SQZ shareholders today, marks another significant milestone for STEMCELL, Canada.

STEMCELL Technologies Announces Successful Asset Purchase Agreement with SQZ Biotechnologies Company

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (OTC: SQZB) (the “Company” or “SQZ”) today announced the results for the proposals considered and voted upon by its shareholders at its special meeting on February 29, 2024 (the “Special Meeting”). The Company reported that all of the proposals submitted to its shareholders in connection with the previously announced asset sale pursuant to that certain Asset Purchase Agreement (the “Purchase Agreement”), dated December 21, 2023, ent.

Asset Sale and Plan of Liquidation and Dissolution Approved by SQZB Shareholders

WATERTOWN, Mass.WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (OTC: SQZB), focused on unlocking the full potential of cell therapies, today reported third quarter 2023 financial results and recent portfolio updates. “We have taken difficult, but necessary, steps to reduce our operating expenses as we explore strategic alternatives,” said Howard Bernstein, M.D., Ph.D., Interim Chief Executive Officer and Member of the Board of Directors. “The Management Team and the Board firmly.

SQZ Biotechnologies Reports Third Quarter 2023 Financial Results and Recent Portfolio Updates

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (OTC: SQZB), focused on unlocking the full potential of cell therapies, presented clinical data for three programs focused on the treatment of Human Papillomavirus 16 positive (HB16+) driven cancers at the Society for Immunotherapy of Cancer Annual Meeting 2023. “Our programs have shown a favorable safety profile and the ability to effect clinical benefit for patients,” said Howard Bernstein, M.D., Ph.D., Interim Chief Executive Off.

SQZ Biotechnologies Reports Data for Clinical Programs at the Society for Immunotherapy of Cancer Annual Meeting

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (OTC: SQZB), focused on unlocking the full potential of cell therapies, today reported second quarter 2023 financial results and recent portfolio updates. “We made steady progress in the enrollment of our two clinical trials and anticipate monotherapy data readouts for each program later this year,” said Howard Bernstein, M.D., Ph.D., Interim Chief Executive Officer and Member of the Board of Directors. “We recently announced our in.

SQZ Biotechnologies Reports Second Quarter 2023 Financial Results and Recent Portfolio Updates

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (OTC: SQZB) (the “Company” or “SQZ”) today announced that Roche has determined that it will not exercise its option for HPV 16 positive solid tumors under the SQZ-APC-HPV program. SQZ Biotechnologies will regain full clinical development and future commercialization rights for its programs targeting HPV 16 positive tumors. The Company intends to explore potential strategic partnerships to support the advancement of its oncology prog.

News for SQZ Biotechnologies Co Stock (SQZB)